Moreover, according to the results established for ICI treatment outcomes in melanoma, metastatic gastric cancer, and bladder cancer, the authors have found that predictions made using network-based biomarkers are more precise than those based on the expression levels of ICI targets, including PD1, PD-L1, or CTLA-4 [228]. This evidence concerns the gene CTLA4 and urinary bladder carcinoma.